Aktienanalyse zu Pulmonx Corp (LUNG)LUNGPulmonx Corp

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Pulmonx Corp (LUNG) appears to be a good buy right now due to its current price of $2.58, which is significantly below the analyst price target of $4, indicating a potential upside of 55%. Additionally, the stock has shown a strong 5-day change of +32.31% and a 20-day change of +37.23%, reflecting positive momentum. The RSI is at 59, suggesting it is not overbought yet. However, the main risk is the forward P/E ratio of 28.33, which indicates high expectations for future earnings despite current losses.